Moxonidine (BDF5895) hydrochloride是一种口服活性的咪唑啉1型受体(I1-R)激动剂。该药物通过激活咪唑啉I1受体和α2肾上腺素能受体来影响氧化低密度脂蛋白的摄取，能够减少动脉粥样硬化病变并降低血压，在高血压、心力衰竭及动脉粥样硬化的研究中具有应用价值。

[1] Wang Y, Nguyen DT, Anesi J, Alramahi A, Witting PK, Chai Z, Khan AW, Kelly J, Denton KM, Golledge J. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24(4):3857. doi: 10.3390/ijms24043857. PMID: 36835270; PMCID: PMC9960795.